Key result
This review summarizes the effects of ramipril on myocardial infarction, death, diabetes mellitus, and stroke in patients at high cardiovascular risk without heart failure.
Why the study?
Does ramipril reduce myocardial infarction, death, diabetes mellitus, and stroke in patients with a high risk for cardiovascular events without pre-existing left ventricular dysfunction or heart failure?
Does ramipril reduce myocardial infarction, death, diabetes mellitus, and stroke in patients with a high risk for cardiovascular events without pre-existing left ventricular dysfunction or heart failure?
This review summarizes the cardiovascular benefits of ramipril in high-risk patients without heart failure, primarily focusing on the HOPE study.
May support ramipril in high-risk patients without HF; leaves open need for updated trials in contemporary populations.
Several clinical studies demonstrate a beneficial role of angiotensin-converting enzyme (ACE) inhibitors in patients with myocardial infarction, hypertension and diabetes mellitus. This review focuses on the effects of ramipril, a weak inhibitor of ACE that is rapidly hydrolyzed to ramiprilat, an active metabolite. The Heart Outcome Prevention Evaluation (HOPE) study evaluated the effects of ramipril in patients with a high risk for cardiovascular events without pre-existing left ventricular dysfunction or heart failure. In this review, we summarized the effects of ramipril on myocardial infarction, death, diabetes mellitus, and stroke.
No takes yet. Share an insight, caveat, or question.
Khazaei et al. (2009) conducted a review in High risk for cardiovascular events. Ramipril was evaluated on Myocardial infarction, death, diabetes mellitus, and stroke. This review summarizes the effects of ramipril on myocardial infarction, death, diabetes mellitus, and stroke in patients at high cardiovascular risk without heart failure.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: